Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Tikun Olam-Cannbit Pharmaceuticals Ltd
  6. News
  7. Summary
    TKUN   IL0010843675

TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD

(TKUN)
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Tikun Olam-Cannabit and Opiostop LLC Are Establishing A JV to Conduct A Clinical Study on Treating Opioid Addiction, Using Cannabit Medical Cannabis Strains, That Is Undergoing Fast-Track Registration by the FDA

02/03/2021 | 07:00am EST

Cannabit Ltd., will be the exclusive supplier of medical cannabis for clinical research into treatment for opioid addiction. The company will be entitled to exclusive marketing of the treatment method in Israel, Germany and England too. The study will be done using a patent for an addiction treatment method that is currently undergoing registration by JFM Technology Holdings LLC, for which Opiostop has received an exclusive, unlimited license, under the U.S.FDA's fast-track. The U.S. company Opiostop will provide all the financing, the submission of the patent and follow-up submissions, will be responsible for the performance and financing of the clinical trial in the United States, and will see to getting all the licenses for importing into the United States.


ę S&P Capital IQ 2021
All news about TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD
08/24Tikun Olam-Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended..
CI
08/19Tikun Olam-Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 12 mill..
CI
08/16Tikun Olam-Cannbit Continues to Expand Its Footprint in the Pharmaceutical Arena
CI
03/30Tikun Olam - Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Full Year End..
CI
03/25Canonic of Evogene Group and Tikun Olam-Cannbit, Sign Production and Distribution Agree..
CI
02/03Tikun Olam-Cannabit and Opiostop LLC Are Establishing A JV to Conduct A Clinical Study ..
CI
01/28Tikun Olam-Cannbit Develops Revolutionary System for the Characterization of Genetic Fi..
CI
2020Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 11.528 million in ..
CI
2019Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 10.0344 million in..
CI
2019Cannbit Pharmaceuticals Ltd competed the acquisition of Israel activities from Tikun Ol..
CI
More news
Financials
Sales 2020 21,7  6,85  6,85 
Net income 2020 -32,9 M -10,4 M -10,4 M
Net Debt 2020 5,33 M 1,69 M 1,69 M
P/E ratio 2020 -5,03x
Yield 2020 -
Capitalization 128 M 40,4 M 40,5 M
EV / Sales 2019 -
EV / Sales 2020 8 863 230x
Nbr of Employees 100
Free-Float 63,7%
Chart TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD
Duration : Period :
Tikun Olam-Cannbit Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Ifat Kariv Chief Executive Officer & Director
Tony Klein Chief Financial Officer
Eitan Ben-Eliahu Chairman
Ronen Harel Independent External Director
Revital Aviram External Director